MGC Pharma receives approval for dementia trial
Published 27-AUG-2018 11:52 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharmaceuticals (ASX:MXC) is one step closer to trialling its promising GMP certified CogniCannTM formulation on patients with mild dementia and Alzheimer’s.
The company, in partnership with the Institute for Health Research at the University of Note Dame (UNDA) in WA, has received Human Research Ethics Committee (HREC) approval to conduct a Phase two clinical trial utilising its CogniCannTM compound.
CogniCannTM features a THC:CBD ratio specifically formulated for the treatment of key dementia symptoms.
The 16 week trial will be overseen by the University’s Institute for Health Research and is projected to commence in early 2019.
The trial will utilise randomised, double-blind, crossover and placebo-control design to observe the behavioural changes and quality of life in patients living in residential aged care homes.
A total of 50 WA patients aged 65 years and older will partake in the CogniCannTM trial, alongside a series of pre and post treatment surveys to assess residential staff and family member’s perception towards the use of the treatment.
The trial has been designed by MXC’s expert Medical Advisory Board led by Professor Uri Kramer and the research team at UNDA, an institution where health and medical research have been rated as ‘above world standard’.
Upon completion of the trial, MXC will possess all IP and results, with the researchers to acquire a worldwide non-exclusive royalty free licence to use the project’s IP for non-commercial research (including research publications).
Of course, it should be noted here that MXC is still in its early stages and anything can happen, so investors should seek professional financial advice if considering this stock for their portfolio.
The impending commencement of the trial is another milestone for MXC, which is well on track to becoming a bio-pharmaceutical company boasting a plethora of medicinal cannabis formulations for a wide range of treatments.
The company’s extensive range of GMP certified pharmaceuticals are engineered and produced within its EU facility, facilitating a seed-to-pharma business model.
MXC Co-founder and Managing Director Roby Zomer commented on the trial’s approval, “We are pleased to have received ethics approval for our Phase II clinical trial assessing the effects of our medicinal cannabis medicine, CogniCannTM on patients with mild dementia and are excited to start working with the superior team of researchers at the University of Notre Dame.
“We are building strong relationships in the medical research industry and see this as taking the next step in our strategic growth and development of our seed-to-pharma capabilities,” he said.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
